Cost effectiveness analysis of ceftriaxone and levofloxacin for therapy of urinary tract infection at Soebandi public hospital
Abstract
Background: An ideal therapeutic option should be effective and have a low cost. The first-line therapy of urinary tract infection (UTI) includes cephalosporin and fluoroquinolone. Objective: To find out which antibiotic therapy is more cost-effective between ceftriaxone and levofloxacin using a cost-effectiveness analysis test. Method: The study was conducted retrospectively using medical records and patient direct medical cost data for 2019 and 2020. The records of 21 patients met the inclusion criteria. Data processing and decision-making were carried out using descriptive and inferential statistical analysis, average cost-effectiveness (ACER) calculations, and a cost-effectiveness grid. The outcome parameter used in a cost-effectiveness analysis was the percentage of effectiveness of empirical therapy. Result: The results showed that 61.9% of patients received ceftriaxone and 38.1% received levofloxacin. The average length of hospitalisation of UTI patients with levofloxacin therapy was shorter than those treated with ceftriaxone (four versus five days) with a p-value = 0.066. The average cost of ceftriaxone treatment was higher than that of levofloxacin (IDR 2,352,307 versus IDR 1,867,183). Based on statistical analysis carried out on each component of direct medical cost, the results were not significantly different between the cost of treatment with ceftriaxone or levofloxacin (p = 0.107). The percentage of effectiveness of empirical therapy using levofloxacin was…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.